



OSE Immunotherapeutics to Host Key Opinion Leader Meeting on Novel Treatments in Non-Small Cell Lung Cancer

Meeting Scheduled for May 30, 2019 in New York City

Nantes, May 22, 2019 – 6:00 PM CET- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today announced that it will host a Key Opinion Leader (KOL) meeting on novel treatments in non-small cell lung cancer (NSCLC) on May 30th in New York City.

The meeting will feature a presentation by KOL Benjamin Besse, M.D., Ph.D., from the Gustave Roussy Cancer Campus, Villejuif, France, who will discuss the current treatment landscape and unmet medical need in patients with thoracic cancers, including non-small cell lung cancer (NSCLC). Dr. Besse will be available at the conclusion of the event to answer questions.

At the event, the management team of OSE Immunotherapeutics will also provide an overview of the Company's development plans for Tedopi[®], a proprietary combination of nine optimized neo-epitopes plus one epitope giving universal helper T cell response targeting T cell activation, and will be available for questions. Tedopi[®] is OSE's most advanced product, currently in Phase 3 in patients with NSCLC after immune checkpoint inhibitor failure. Tedopi[®] is also in Phase 2 status in pancreatic cancer, a trial sponsored by the GERCOR cooperative group in oncology.

Dr. Benjamin Besse is a professor of Medical Oncology and a full time cancer specialist at Gustave Roussy Cancer Campus. Currently, Dr. Besse is Head of the Cancer Medicine Department at Gustave Roussy Cancer Campus, Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Group and coordinator of the French network for thymic malignancies. His main research interests include: the application of molecular abnormalities to personalize treatment, circulating biomarkers, early drug development in thoracic tumors and thymic malignancies. He has authored/co-authored more than 250 peer-reviewed papers.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please **RSVP** in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live **webcast**.

ABOUT OSE Immunotherapeutics

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. The most advanced therapeutic-candidate, Tedopi[®], is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1) and in Phase 2 testing in pancreatic cancer in combination with checkpoint inhibitor Opdivo[®]. FR104 (an anti-CD28 mAb) has successfully completed Phase 1 testing and has potential to treat autoimmune diseases. BI 765063 (OSE-172) (anti-SIRPa monoclonal antibody) is under a license and collaboration

agreement with Boehringer Ingelheim; this checkpoint inhibitor has received CTA from French and Belgian health authorities for a Phase 1 clinical trial in multiple cancer indications. BiCKI® is a bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) and targeting innovative targets. OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) is partnered with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases; in parallel, Servier plans a development in the Sjögren syndrome. OSE-127 is currently under Phase 1 clinical trial.

Click and follow us on Twitter and LinkedIn



Contacts

OSE Immunotherapeutics
Sylvie Détry
Sylvie.detry@ose-immuno.com
+33 153 198 757

U.S. Media: LifeSci Public Relations
Darren Opland, Ph.D.
darren@lifescipublicrelations.com
+1 646 627 8387

French Media: FP2COM
Florence Portejoie
fportejoie@fp2com.fr
+33 607 768 283

U.S. and European Investors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2019, including the annual financial report for the fiscal year 2018, available on the OSE Immunotherapeutics' website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.